Meet with… NCATS

Oct 23 2014

SF BAY AREA EVENT Translation is a team sport and NCATS wants to play

Program Overview:
Meet with the newest institute at the NIH called The National Center for Advancing Translational Science (NCATS). By design, NCATS was formed to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster.

NCATS directly addresses the obstacles scientists face when developing a novel drug, device or other intervention. They are committed to uncovering new technologies and other approaches that could greatly accelerate the development and deployment of solutions that all translational researchers can use.

The NCATS approach is distinct in many ways and has already made a significant impact. Successes include 19 INDs that have been cleared by the FDA, twelve projects have been evaluated in clinical trials, and three agents have gone as far as Phase II human clinical trials. Additionally, third-party investors have licensed seven agents that have been developed through NCATS programs.

Join us to learn more about NCATS and their innovative approach. Following an overview of NCATS' opportunities and key areas of interest, don't miss the opportunity to introduce yourself during the networking lunch. Finally, for those companies who apply online and are approved, one-on-one meetings with NCATS will provide a forum to further discuss your company.

NCATS is seeking to collaborate with companies focusing on translating bench top discoveries to clinical hypothesis testing. Leaders from the life science industry are encouraged to apply today to meet with a representative from NCATS!

10:00 AM | Registration & Networking
10:30 AM | Presentation & Q&A
12:00 PM | Lunch & Networking
1:00 PM | One-on-one Meetings*
4:30 PM | Program Close

*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period ends October 9. APPLY HERE

NIH NCATS Participating Representative:
John McKew, Ph.D. | Acting Scientific Director; Division of Preclinical Innovation, National Center for Advancing Translational Science, National Institutes of Health read bio»

About the National Center for Advancing Translational Sciences:
The National Center for Advancing Translational Sciences (NCATS) is the newest of 27 Institutes and Centers (ICs) at the National Institutes of Health (NIH). This Center was established in December 2011 to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster. The mission of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Read more about NCATS»

Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until October, 22 (or full).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on on Thursday, October 9. Your application will be reviewed and you will be notified of acceptance on Thursday, October 16, 2014. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

UCSF Mission Bay
Byers Hall Room 212
600 16th Street
San Francisco, CA 94158

NIH NCATS Representative's Biographies:
John McKew John C. McKew, Ph.D | Acting Scientific Director, Division of Preclinical Innovation, National Center for Advancing Translational Science, National Institutes of Health
Dr. McKew is the Acting Scientific Director of the Division of Preclinical Innovation at the National Center for Advancing Translational Sciences (NCATS) within the NIH. His responsibilities include developing the Therapeutics for Rare and Neglected Disease (TRND) program and the Bridging Interventional Development Gaps program (BrIDGs; former NIH-RAID program). Both of these programs focus on novel public/private partnerships to advance collaborative drug discovery projects through pre-clinical development into early clinical development. These collaborative projects are advanced using a combination of internal scientific resources as well as government contracts. Prior to joining the NIH, Dr. McKew held a Director level position at Wyeth Research in Cambridge, Massachusetts where he spent a total of 17 years. One role at Wyeth he held comprised leading a hit-to lead chemistry group supporting cardiovascular, musculoskeletal and metabolic disease therapeutic areas. Prior to that Dr. McKew spent 10 years working in the inflammation therapeutic area resulting in multiple compounds entering clinical evaluation. His research interests include rare and neglected disease research, medicinal chemistry, synthetic methodology, and tool compounds to probe biology. These interests have resulted in >25 publications, 10 Granted US Patents and multiple podium presentations. John also enjoys sharing his passion for science with others. This has prompted him to become course director and lecturer in GMS PM 881 "Drug Discovery and Development" a graduate level course in the Department of Pharmacology and Experimental Therapeutics which resulted in his appointment as an Adjunct Associate Professor Boston University School of Medicine. He has also taken an active role in the Northeastern Section of the American Chemical Society and has served as the Chair-Elect, Chair and the Immediate Past Chair.
Dr. McKew graduated from State University of New York at Stony Brook with B.S. degrees in Chemistry and Biochemistry. He completed his Ph.D. in Organic Chemistry at University of California, Davis and held post-doctoral research positions at the University of Geneva and Firmenich, SA.

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by Janssen Labs is to help start-up entrepreneurs as well as the academic community connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include: Wellcome Trust, Correlation Ventures, MedImmune Ventures, NCI, Mercury Fund and Thomas McNerney & Partners.